Christoph U. Correll, MD

Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study

Background: Antipsychotic treatment of schizophrenia is often associated with increased rates of metabolic syndrome (MetSy), as defined by criteria for waist circumference, triglycerides,...

Suresh Durgam , MD;

Christoph U. Correll , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

John Edwards , MD, MBA;

Richard Chen , PhD;

10/08/2020

A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Anti-psychotic Medications

Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...

Kruti Joshi , MPH, MD;

Edward S. Kim , MD, FACP, MBA;

Christoph U. Correll , MD;

Charmi Patel , BS , RN, BSN, MPH;

Amber Martin , BS;

Rebecca Goulding , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Emma Schiller , BA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents With Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: Few studies have prospectively evaluated short- or long-term antipsychotic efficacy in treatment-naïve (vs. previously treated) first-episode schizophrenia. The aim of this po...

Robert Goldman , PhD;

Christoph U. Correll , MD;

Michael Tocco , PhD;

Jay Hsu , PhD;

11/22/2019

Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...

Jelena Saillard , MS, MBA;

Christoph U. Correll , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

Kimberly Vanover , PhD;

11/22/2019

Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study

BACKGROUND: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dysregulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist s...

Christoph U. Correll , MD;

11/22/2019

Neurobiology of Treatment-Resistant Schizophrenia

Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) m...

John Kane , MD;

Steven Potkin , MD;

Jean-Pierre Lindenmayer , MD;

Ofer Agid , MD;

Christoph U. Correll , MD;

Stephen Marder , MD;

Oliver Howes , MD;

03/01/2019

Effects of Long-Term Valbenazine on Psychiatric Status in Patients With Tardive Dyskinesia and a Primary Mood Disorder

Objective: In two long-term phase 3 studies, sustained TD improvements were observed in participants who received once-daily treatment with valbenazine (40 or 80 mg). Data from these stud...

Joshua Burke , MS;

Scott Siegert , PharmD;

Gary Remington , MD, PhD;

Rachel Weber , PhD;

Leslie Lundt , MD;

Khodayar Farahmand , PharmD;

Christoph U. Correll , MD;

Roger McIntyre , MD, FRCPC;

03/01/2019

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)

Abstract: Background: In the 5-week, randomized, double-blind, placebo-controlled, phase 2 EMERGENT-1 study (NCT03697252), the M1/M4 preferring muscarinic receptor agonist KarXT met prima...

Christoph U. Correll , MD;

Jennifer Cavan ;

01/26/2023

Efficacy and Safety of Paliperidone Palmitate 6-Month Formulation: A 3-Year Analysis in Adults With Schizophrenia

This analysis assessed the efficacy and safety of paliperidone palmitate 6-month (PP6M) in adults with schizophrenia who remained relapse free after a 1-year double-blind study (NCT033453...

Christoph U. Correll , MD;

10/26/2023

Videos

Challenges and Limitations When Using Oral Antipsychotics in Bipolar Disorder Treatment

02/15/2024

Christoph U. Correll , MD;

In this interview from on-site at Psych Congress 2023, Christoph Correll, MD, examines the challenges with using oral antipsychotics when treating patients with bipolar disorder and how they might contribute to non-adherence.

In this interview from on-site...

02/15/2024

Psych Congress Network